Opposite roles for cannabidiol and ÎŽ-9-tetrahydrocannabinol in psychotomimetic effects of cannabis extracts: a naturalistic controlled study
Authors:
Alberto Sainz-Cort, Daniel Jiménez-Garrido, Elena Muñoz-Marrón, Raquel Viejo-Sobera, Joost Heeroma, and José Carlos Bouso.
Journal:
Journal of Clinical Psychopharmacology
Year:
2021
About the study
The aim of this study was to determine how CBD could counteract the subjective and psychotomimetic effects of THC in a contextual setting, expecting that participants under the effects of THC would show greater subjective and psychotomimetic effects when compared with CBD and placebo, and that THC-CBD coadministration would counteract subjective and psychotomimetic effects of THC.
The authors designed a contextual, naturalistic, randomized, double blind, placebo-controlled, and crossover study to test the subjective effects of different types of cannabis extracts on users from the CSC Strain Hunters Club in Barcelona.
The study adds more evidence about the acute positive psychotic-like effects of THC and the antipsychotomimetic effects of CBD. Moreover, it supports the potential antipsychotic properties of CBD, making it a suitable substance for both the treatment of psychotic disorders and the use of medical cannabis.
Abstract
Background: Although ÎŽ-9-tetrahydrocannabinol (THC), the main cannabinoid from the cannabis plant, is responsible for the psychotomimetic effects of cannabis, cannabidiol (CBD), the second most abundant cannabinoid in the cannabis plant, does not show any psychotomimetic effect. Cannabidiol has even been proposed to be antipsychotic and to counteract some of the psychotomimetic effects of THC. The aim of this study was to test the potential antipsychotomimetic effects of CBD.
Method: Eighteen members from a cannabis social club were tested for subjective and psychotomimetic effects under the effects of different full-spectrum cannabis extracts containing either THC, CBD, THC + CBD, or placebo in a naturalistic, randomized, double-blind, crossover, placebo-controlled study.
Results: Results showed that participants under the effects of THC + CBD showed lower psychotomimetic scores in subjective scales when compared with THC alone. Subjective scores were lower under the effects of CBD and placebo when compared with THC + CBD. Cannabidiol and placebo did not show any psychotomimetic effect.
Conclusions: This study provides evidence for both the psychotomimetic effects of THC and the antipsychotomimetic effects of CBD when it is coadministered with THC in real-world situations, which can be very relevant for the clinical practice of medical cannabis. Ultimately, this study substantiates the link between the endocannabinoid system and psychotic-like symptoms and has important implications for the understanding of schizophrenia and the therapeutic potential of CBD as an antipsychotic. Lastly, we demonstrate how reliable methodologies can be implemented in real situations to collect valid ecological evidence outside classic laboratory settings.
Photo by CRYSTALWEED cannabis on Unsplash.
Categories:
Studies & papers
, Cannabis
Tags:
study
, CBD
, subjective effects
, antipsychotic
, THC
, cannabis
, scientific research